ClinicalTrials.Veeva

Menu

Expression of AMP-activated Protein Kinase (AMPK) Protein in Lung Adenocarcinoma

C

China Medical University

Status

Unknown

Conditions

Lung Adenocarcinoma

Study type

Observational

Funder types

Other

Identifiers

NCT01249066
DMR99-IRB-096

Details and patient eligibility

About

AMP-activated protein kinase (AMPK) is an evolutionally conserved protein kinase that serves as an energy guardian to help cells adapt to various metabolic stress including hypoxia. Because the role of AMPK in cancers has not been fully elucidated, in this study we investigated the expression and activation of AMPK in lung adenocarcinoma (LADC) cells and tissue.

Enrollment

100 estimated patients

Sex

All

Ages

25 to 85 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Lung cancer received operation lobectomy in CMUH

Exclusion criteria

  • History of uremia, other malignant disease, and liver cirrhosis
  • History of pneumonia and pulmonary tuberculosis
  • History of long period of medications.

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems